Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors

Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors


The study identified novel HIV-1 capsid inhibitors with highly potent antiviral activity and a favorable resistance profile to existing ARVs in vitro. The data are being presented in an oral session at the 2017 Conference on Retroviruses and Opportunistic Infections in Seattle.



from Biotech News